DGAP-News: Defence Therapeutics Inc.
/ Key word(s): Miscellaneous
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE THERAPEUTICS RETAINS THE HUS COMPREHENSIVE CANCER CENTER TO OPTIMIZE ITS ACCUM-T-DM1 ADC THERAPEUTIC
Vancouver, BC, Canada, June 7th, 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), is pleased to announce, after very encouraging preliminary in vivo results, the establishment of a collaboration with the HUS Comprehensive Cancer Center at Helsinki, Finland for the optimization of Defence's Accum-T-DM1 ADC Therapeutic. This Cancer Center is Finland's largest and most versatile cancer treatment center, their expertise is internationally highly valued and their treatment results are world-class.
T-DM1 (Ado-trastuzumab, Kadcyla(R)) approved by the FDA in 2013 to treat women with metastatic HER2-positive breast cancer surpassed $1 billion in annual sales in 2019 to become the first ADC to hit blockbuster status. The Kadcyla(R) ADC antibody portion of this drug serves as a homing device to the chemotherapeutic drug emtansine. Clinical and pre-clinical studies have shown that intracellular drug delivery to breast cancer cells may not be optimal causing treatment resistance and recurrence.
Combining the Accum technology to the Kadcyla(R) ADC is expected to amplify the therapeutic index of the drug while potentially minimizing side effects observed in patients undergoing the therapy. Defence's Accum platform has been developed and tested in vitro to enhance the intracellular drug delivery on multiple ADCs that are FDA approved or under development.
"We have a long-standing experience in the field of ADC therapeutics, and we believe that the HUS Comprehensive Cancer Center represents an ideal collaborator for the ongoing development of the optimized Accum-T-DM1 conjugate," said Sebastien Plouffe, Chief Executive Officer of Defence Therapeutics. "We look forward to the continued advancement of our Accum-modified pipeline," he added.
Currently, the T-DM1 regiment consists of a 3-week treatment cycle for up to 14 cycles. By linking Defence's Accum to T-DM1, the regiment will most likely be shorter due to the enhanced therapeutic effect of the ADC.
The Global cancer immunotherapy market is worth over $100 billion annually.
For further information:
07.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Company:||Defence Therapeutics Inc.|
|1680 - 200 Burrard St|
|Listed:||Regulated Unofficial Market in Frankfurt, Stuttgart; Toronto|
|EQS News ID:||1204645|
|End of News||DGAP News Service|